Michael Rice - Feb 24, 2022 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
CEO, Director
Signature
/s/ Michael Rice
Stock symbol
BLFS
Transactions as of
Feb 24, 2022
Transactions value $
$0
Form type
4
Date filed
3/9/2022, 08:21 PM
Previous filing
Feb 14, 2022
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Award +70.1K +27.09% 329K Feb 24, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Restricted Stock Award Award $0 +70.1K $0.00 70.1K Feb 24, 2022 Common Stock 70.1K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2022 compensation.
F2 The amount represented in Column 5 of Table I reflects the amount of securities beneficially owned by the reporting person as of the transaction date reported herein. It does not give effect to the transaction reported by the reporting person on the Form 4 filed by the reporting person on March 3, 2022.
F3 The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.